+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adult Preventable Vaccines Market - Global Forecast 2025-2030- Product Image
Adult Preventable Vaccines Market - Global Forecast 2025-2030- Product Image
Sale

Adult Preventable Vaccines Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136452
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The adult preventable vaccines market is undergoing significant transformation, spurred by shifting demographics, technological advances, and evolving policy frameworks. Senior executives seeking actionable intelligence on market direction and strategic priorities will find comprehensive insights on growth drivers, regulatory impacts, and innovation pathways within this report.

Market Snapshot: Adult Preventable Vaccines

The global adult preventable vaccines market is positioned for substantial growth, fueled by increased awareness of adult immunization and a rising prevalence of preventable diseases among aging populations. Recent years have witnessed higher adoption rates across developed and emerging regions, bolstered by intensified public health initiatives and continuous advancements in vaccine technology. The industry’s focus is expanding beyond childhood vaccination, with adult cohorts displaying heightened vulnerability to infections such as influenza, HPV, pneumococcal disease, and others. Regulatory bodies are streamlining pathways for new vaccine approvals, and cross-industry partnerships are playing an instrumental role in shaping future market strategies.

Scope & Segmentation

This report delivers in-depth coverage and segmentation of the adult preventable vaccines market, highlighting opportunities by vaccine type, distribution channel, age group, technology platform, payment type, region, and competitive landscape.

  • Vaccine Types: Hepatitis B (e.g., Engerix-B, Heplisav-B, Recombivax HB), HPV (Cervarix, Gardasil, Gardasil 9), Influenza (Adjuvanted, Quadrivalent, Trivalent), Meningococcal (Menactra, MenQuadfi, Menveo), Pneumococcal (PCV13, PPSV23), Shingles (Shingrix, Zostavax), Tdap (Adacel, Boostrix)
  • Distribution Channels: Clinic, Hospital, Pharmacy, Public Health Facility
  • Age Groups: 18 to 29, 30 to 49, 50 to 64, 65 plus
  • Technology Platforms: Conjugate, Inactivated, Live Attenuated, Recombinant
  • Payment Types: Government Funded, Out Of Pocket, Private Insurance
  • Key Geographies: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, UAE, South Africa), Asia-Pacific (China, India, Japan, Australia, South Korea and others)
  • Leading Companies: Pfizer Inc., Moderna, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Sanofi S.A., Johnson & Johnson, AstraZeneca PLC, CSL Limited, Novavax, Inc., Takeda Pharmaceutical Company Limited

Key Takeaways

  • Adult preventable vaccination strategies are increasingly data-driven, integrating digital immunization records and predictive analytics to target at-risk populations and improve coverage rates.
  • Breakthroughs in platforms such as recombinant, conjugate, and next-generation adjuvants are expanding vaccine efficacy and product pipelines, targeting needs of aging and high-risk demographics.
  • Public and private sector partnerships—such as expanded roles for pharmacies and clinics—are enhancing vaccine accessibility and driving program adoption in both centralized and decentralized regions.
  • Shifting payment frameworks, including adaptive reimbursement and co-funding models, are overcoming historical barriers related to out-of-pocket expenses and improving affordability in mature populations.
  • Regional dynamics play a crucial role: the Americas benefit from established partnerships, EMEA exhibits regulatory and procurement complexity, while Asia-Pacific's rapid expansion must address access disparities between urban and rural areas.
  • Continued research, capacity building, and operational resilience are necessary as regulatory and trade developments require agile supply chains and strategic planning across global and regional markets.

Tariff Impact: Strategic Shifts for Vaccine Producers

The 2025 changes to United States import tariffs have raised production costs for adult preventable vaccine manufacturers, driving a reassessment of sourcing and manufacturing strategies. Companies are responding by diversifying supplier agreements, exploring localized sourcing, and considering regional fill-finish operations to offset cost fluctuations and supply interruptions. These moves underscore the critical importance of managing supply chain risks in a volatile global trade environment.

Methodology & Data Sources

This report’s findings are based on a thorough combination of primary and secondary research. In-depth interviews with industry leaders, health authorities, and supply chain executives provided qualitative perspectives, while a review of peer-reviewed journals and regulatory filings ensured quantitative validation. Analytical techniques such as segmentation analysis and scenario modeling underpin the report's objectivity and depth.

Why This Report Matters

  • Offers a comprehensive foundation to support strategic planning and investment decisions for stakeholders in the adult preventable vaccines market.
  • Identifies actionable insights on technology adoption, distribution optimization, and evolving payment frameworks to drive sustainable growth.
  • Equips decision-makers with clarity on regulatory and trade developments, risk mitigation strategies, and emerging opportunities regionally and globally.

Conclusion

This report delivers a clear, factual overview for senior leaders aiming to optimize strategies within the adult preventable vaccines sector. As adult immunization demands evolve, the insights herein enable proactive planning to elevate public health and secure long-term market positioning.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of mRNA technology for adult influenza and RSV vaccination strategies
5.2. Increased focus on combination vaccines to simplify adult immunization schedules
5.3. Government-funded booster programs targeting aging populations and high-risk groups
5.4. Expansion of pharmacy-led vaccination services to improve adult vaccine accessibility
5.5. Growing utilization of digital health platforms for adult immunization reminders and tracking
5.6. Heightened demand for travel-related adult vaccines amid resumption of international tourism
5.7. Integration of immunization records with electronic health records for adult patient monitoring
5.8. Development of single-dose and thermostable vaccine formulations for resource-limited settings
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Adult Preventable Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Hepatitis B Vaccine
8.2.1. Engerix-B
8.2.2. Heplisav-B
8.2.3. Recombivax HB
8.3. HPV Vaccine
8.3.1. Cervarix
8.3.2. Gardasil
8.3.3. Gardasil 9
8.4. Influenza Vaccine
8.4.1. Adjuvanted
8.4.2. Quadrivalent
8.4.3. Trivalent
8.5. Meningococcal Vaccine
8.5.1. Menactra
8.5.2. MenQuadfi
8.5.3. Menveo
8.6. Pneumococcal Vaccine
8.6.1. PCV13
8.6.2. PPSV23
8.7. Shingles Vaccine
8.7.1. Shingrix
8.7.2. Zostavax
8.8. Tdap Vaccine
8.8.1. Adacel
8.8.2. Boostrix
9. Adult Preventable Vaccines Market, by Distribution Channel
9.1. Introduction
9.2. Clinic
9.3. Hospital
9.4. Pharmacy
9.5. Public Health Facility
10. Adult Preventable Vaccines Market, by Age Group
10.1. Introduction
10.2. 18 To 29
10.3. 30 To 49
10.4. 50 To 64
10.5. 65 Plus
11. Adult Preventable Vaccines Market, by Technology Platform
11.1. Introduction
11.2. Conjugate
11.3. Inactivated
11.4. Live Attenuated
11.5. Recombinant
12. Adult Preventable Vaccines Market, by Payment Type
12.1. Introduction
12.2. Government Funded
12.3. Out Of Pocket
12.4. Private Insurance
13. Americas Adult Preventable Vaccines Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Adult Preventable Vaccines Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Adult Preventable Vaccines Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Moderna, Inc.
16.3.3. Merck & Co., Inc.
16.3.4. GlaxoSmithKline plc
16.3.5. Sanofi S.A.
16.3.6. Johnson & Johnson
16.3.7. AstraZeneca PLC
16.3.8. CSL Limited
16.3.9. Novavax, Inc.
16.3.10. Takeda Pharmaceutical Company Limited
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. ADULT PREVENTABLE VACCINES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ADULT PREVENTABLE VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ADULT PREVENTABLE VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ADULT PREVENTABLE VACCINES MARKET: RESEARCHAI
FIGURE 26. ADULT PREVENTABLE VACCINES MARKET: RESEARCHSTATISTICS
FIGURE 27. ADULT PREVENTABLE VACCINES MARKET: RESEARCHCONTACTS
FIGURE 28. ADULT PREVENTABLE VACCINES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ADULT PREVENTABLE VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ENGERIX-B, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ENGERIX-B, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPLISAV-B, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPLISAV-B, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY RECOMBIVAX HB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY RECOMBIVAX HB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY CERVARIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY CERVARIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY GARDASIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY GARDASIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY GARDASIL 9, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY GARDASIL 9, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TRIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TRIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENQUADFI, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENQUADFI, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PCV13, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PCV13, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PPSV23, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PPSV23, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGRIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ZOSTAVAX, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ADACEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY ADACEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY BOOSTRIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY BOOSTRIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PUBLIC HEALTH FACILITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PUBLIC HEALTH FACILITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 18 TO 29, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 18 TO 29, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 30 TO 49, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 30 TO 49, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 50 TO 64, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 50 TO 64, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 65 PLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY 65 PLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY GOVERNMENT FUNDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY GOVERNMENT FUNDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY OUT OF POCKET, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY OUT OF POCKET, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES ADULT PREVENTABLE VACCINES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 165. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 166. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 167. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 168. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 169. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 170. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 171. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 172. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 173. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 174. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 175. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 176. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 177. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 178. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 179. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 180. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 181. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 186. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 187. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 188. CANADA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 211. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. MEXICO ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY PAYMENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ADULT PREVENTABLE VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY HPV VACCINE, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY INFLUENZA VACCINE, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY PNEUMOCOCCAL VACCINE, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY SHINGLES VACCINE, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY TDAP VACCINE, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM ADULT PREVENTABLE VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 308. UNITED

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Adult Preventable Vaccines Market report include:
  • Pfizer Inc.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Johnson & Johnson
  • AstraZeneca PLC
  • CSL Limited
  • Novavax, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Polypeptide Vaccine Market - Global Forecast 2025-2030 - Product Image

Polypeptide Vaccine Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Influenza Vaccine Market - Global Forecast 2025-2030 - Product Image

Influenza Vaccine Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Influenza Vaccine Market: Analysis by Valency, Vaccine Type, Technology, Age Group, Route of Administration, Distribution Channel, and Region - Size, Trends and Forecasts to 2030 - Product Image

Influenza Vaccine Market: Analysis by Valency, Vaccine Type, Technology, Age Group, Route of Administration, Distribution Channel, and Region - Size, Trends and Forecasts to 2030

  • Report
  • 165 Pages
  • Global
From
Hepatitis B Vaccines - Global Strategic Business Report - Product Image

Hepatitis B Vaccines - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Hepatitis B Vaccine Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034) - Product Image

Hepatitis B Vaccine Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • Report
  • 350 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.